Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CNST

Constellation Pharmaceuticals (CNST) Stock Price, News & Analysis

Constellation Pharmaceuticals logo

About Constellation Pharmaceuticals Stock (NASDAQ:CNST)

Key Stats

Today's Range
$33.99
$33.99
50-Day Range
$33.63
$33.99
52-Week Range
$17.00
$39.30
Volume
N/A
Average Volume
940,325 shs
Market Capitalization
$1.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Receive CNST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Constellation Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNST Stock News Headlines

Plc Gsk's Net Worth
Trump said you could learn something from this man
Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.
VHCP Management II, LLC's Net Worth
Constellation Software
See More Headlines

CNST Stock Analysis - Frequently Asked Questions

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) released its quarterly earnings data on Sunday, May, 9th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.79) by $0.05.

Constellation Pharmaceuticals (CNST) raised $80 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Constellation Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Kinross Gold (KGC), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Gilead Sciences (GILD) and OPKO Health (OPK).

Company Calendar

Last Earnings
5/09/2021
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNST
CUSIP
21036U206
Fax
N/A
Employees
154
Year Founded
N/A

Profitability

Net Income
$-126,360,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.63 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.63 billion
Optionable
Not Optionable
Beta
2.59
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:CNST) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners